doi: 10.1016/j.beem.2022.101616 28 WeaverCMGordonCMJanzKFKalkwarfHJLappeJMLewisRet al
Conclusion: NASH risk alleles were prevalent in the MAESTRO-NASH population and did not influence the treatment response to resmetirom Disclosures: Naga Chalasani: Madrigal: Consultant, Zydus, Ipsen, Pfizer, Merck, Altimmune, GSK: Consultant, Exact Sciences: Grant/Research Support, NIH: Grant/Research Support, Dominic Labriola: Nothing to Disclose, Rebecca Taub: Madrigal Pharmaceuticals: Employee, Madrigal Pharmaceuticals: Stock - publicly traded company, Madrigal Pharmaceuticals: Executive role, Quentin Anstee: AstraZeneca, Boehringer Ingelheim, Intercept.: Grant/Research Support, Alimentiv, Akero, AstraZeneca, Axcella, 89Bio: Consultant, Boehringer Ingelheim, Bristol Myers Squibb, Corcept: Consultant, Enyo Pharma, Galmed, Genfit, Genentech, Gilead, GlaxoSmithKl: Consultant, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janss: Consultant, Madrigal, Medpace, Merck, Metadeq, NGMBio, North Sea T: Consultant, Novartis, Novo Nordisk, PathAI, Pfizer, Pharmanest: Consultant, Poxel, Prosciento, Resolution Therapeutics, Roche,: Consultant, Ridgeline Therapeutics, RTI, Shionogi, Terns: Consultant, Fishawack, Integritas Communications, Kenes,: Speaking and Teaching, Novo Nordisk, Madrigal, Medscape, Springer Healthcare: Speaking and Teaching, Elsevier Ltd: Royalties or patent beneficiary 2071 APPLYING THE METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) NOMENCLATURE WITH NATURAL LANGUAGE PROCESSING IN A NATIONAL COHORT Binu John 1 Dustin Bastaich 2 Catherine Mezzacappa 3 Raphaella Ferreira 4 Austen Hentschel 5 Andres Samos 5 Nadim Mahmud 6 Tamar Taddei 3 David Kaplan 7 Marina Serper 8 Bassam Dahman 2 , 1 Miami VA and University of Miami, 2 Virginia Commonwealth University, 3 Yale University, 4 Larkin Community Hospital, 5 Florida International University, 6 Hospital of the University of Pennsylvania, 7 University of Pennsylvania, 8 University of Pennsylvania Health System Background: Although metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are identified as a separate clinical entities, tools to identify patients from electronic health records are lacking
On the other hand, there are substantial differences in the efficacies of some flavonoids in vitro and in vivo
It means we do not yet know what they do in people, at what dose, or over what time frame
This one really pushes the science and has the potential to be disease modifying in a way that almost nothing else in the celiac space right now is
